Overall, our data show that the CYP1B1 (phase I metabolism) genetic polymorphism significantly modifies the risk in AML patients, whereas SULT1A1 polymorphisms (phase II metabolism) modify the risk in ALL patients. The gene discussed is CYP1B1; the disease is acute myeloid leukemia.